Verrica Pharmaceuticals Inc.
VRCA
$6.84
$0.6310.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.62% | 50.17% | 98.80% | 101.19% | 52.08% |
| Total Depreciation and Amortization | -6.73% | -24.90% | -46.20% | -40.42% | -38.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.51% | -67.68% | -37.35% | -59.79% | -43.52% |
| Change in Net Operating Assets | 55.95% | 149.08% | -28.01% | -385.45% | -82.64% |
| Cash from Operations | 27.72% | 71.42% | 213.17% | 38.60% | 36.45% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 97.26% | -9,527.27% | -1,735.94% | -2,247.46% | -2,500.64% |
| Issuance of Common Stock | -- | 17.80% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 84.46% | -- | -- | -- |
| Cash from Financing | 97.04% | -65.40% | -903.53% | -549.22% | -513.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.53% | -61.28% | 163.55% | 16.52% | 18.80% |